Open Monoclonal Technology Announces OmniAb Alliance With Amgen



PALO ALTO, Calif.--(BUSINESS WIRE)--Open Monoclonal Technology, Inc. (OMT) today announced a license that

provides Amgen Inc. with access to OMT's proprietary OmniRat®,

OmniMouse® and OmniFlic(TM) human antibody generation platforms,

jointly known as OmniAb(TM). Amgen becomes OMT's 12th

non-academic partner globally with such multi-platform access.



Dr. Roland Buelow, OMT founder and CEO, said, "Amgen was an early

protein therapeutics leader and became one of a few companies with

transgenic mouse platforms for human antibody discovery in 2005 when

they acquired Abgenix and its XenoMouse®. With the license

from OMT, Amgen further builds on this capability as it gains access to

complementary platforms for development of fully human, mono- and

bispecific antibodies without any target restrictions."

About Open Monoclonal Technology, Inc.

Open Monoclonal Technology, Inc. (OMT) is a leader in genetic

engineering of animals for the generation of human therapeutic

antibodies, naturally optimized human antibodies®,

and the only company in the world with four transgenic animal platforms,

jointly known as OmniAb(TM).





OmniRat® is the industry's first

human monoclonal antibody technology based on rats. It has a complete

immune system with a diverse antibody repertoire and generates

antibodies with human idiotypes as well as wild-type animals make rat

antibodies. OmniMouse® is a

transgenic mouse that complements OmniRat and expands epitope coverage. OmniFlic(TM)

is an engineered rat with a fixed light chain for development of

bispecific, fully human antibodies. UniRat(TM)

is the first transgenic rat generating fully human heavy chain-only

antibodies and nanobodies for polyspecific applications.



All four OmniAb(TM) platforms deliver human antibodies with high affinity,

specificity, expression, solubility and stability. They use patented

technology, have broad freedom to operate and are available worldwide

for all targets and indications.



Current partners include Amgen, Caltech, Celgene, Chugai, Genmab,

Genentech, HanAll, Janssen, Merck KGaA, Pfizer, Roche, Symphogen,

University of Nottingham and several undisclosed biotech and

pharmaceutical companies. Animal hosting and OmniAb antibody discovery

services are available via Antibody Solutions, Panoply Bio and Sage Labs

in the US, Aldevron and Taconic Biosciences in Europe, and WuXi AppTec

in China. For more information, please visit www.omtinc.net.

Write a comment

Comments: 0